846results about How to "Sensitive high" patented technology

Systems and methods for assessment of tissue properties, noninvasively, by acquiring data relating to at least one aspect of intrinsic and/or induced tissue displacement, or associated biological responses, are provided. Data relating to tissue displacement and associated biological changes may be acquired by detecting acoustic properties of tissue using ultrasound interrogation pulses, preferably in a scatter or Doppler detection mode. Based on this data, tissue properties are assessed, characterized and monitored. Specific applications for systems and methods of the present invention include non-invasive assessment and monitoring of intracranial pressure (ICP), arterial blood pressure (ABP), CNS autoregulation status, vasospasm, stroke, local edema, infection and vasculitus, as well as diagnosis and monitoring of diseases and conditions that are characterized by physical changes in tissue properties. Methods and systems for localizing physiological condition(s) and/or biological response(s), such as pain, by targeting and selectively probing tissues using the application of focused ultrasound are also provided.

A sensor for measuring density of a liquid that comprises a float unit having a sealed hollow casing that contains a first magnet and a strain-gauge unit having a sealed hollow casing that contains a strain gauge and a second magnet arranged coaxially to the first magnet. Coaxiality of the magnets is provided by means of a guide rod installed on the casing of the strain-gauge unit and used to guide the float unit by inserting the guide rod into the central opening of the float unit casing. A characteristic feature of the sensor is that changes in the density of the liquid that cause displacement of the float cause detectable deformations of the strain gauge via forces of magnetic interaction between the first and second magnets without physical contact between the magnets. Since the elements of the sensor are located in sealed casings, they are not subject to damage and do not require maintenance.

Methods and systems for localizing intravascular lesion in a body lumen. In exemplary embodiments, the methods comprise providing or acquiring an image of the body lumen and displaying information about the lesion with or on the image. In some configurations the information is obtained with an intravascular catheter.

A new way of mixing instrumental and digital means is described for the general field of wave front sensing. The present invention describes the use, the definition and the utility of digital operators, called digital wave front operators (DWFO) or digital lenses (DL), specifically designed for the digital processing of wave fronts defined in amplitude and phase. DWFO are of particular interest for correcting undesired wave front deformations induced by instrumental defects or experimental errors. DWFO may be defined using a mathematical model, e.g. a polynomial function, which involves coefficients. The present invention describes automated and semi-automated procedures for calibrating or adjusting the values of these coefficients. These procedures are based on the fitting of mathematical models on reference data extracted from specific regions of a wave front called reference areas, which are characterized by the fact that specimen contributions are a priori known in reference areas. For example, reference areas can be defined in regions where flat surfaces of a specimen produce a constant phase function. The present invention describes also how DWFO can be defined by extracting reference data along one-dimensional (1D) profiles. DWFO can also be defined in order to obtain a flattened representation of non-flat area of a specimen. Several DWFO or DL can be combined, possibly in addition with procedures for calculating numerically the propagation of wave fronts. A DWFO may also be defined experimentally, e.g. by calibration procedures using reference specimens. A method for generating a DWFO by filtering in the Fourier plane is also described. All wave front sensing techniques may benefit from the present invention. The case of a wave front sensor based on digital holography, e.g. a digital holographic microscope (DHM), is described in more details. The use of DWFO improves the performance, in particular speed and precision, and the ease of use of instruments for wave front sensing. The use of DWFO results in instrumental simplifications, costs reductions, and enlarged the field of applications. The present invention defines a new technique for imaging and metrology with a large field of applications in material and life sciences, for research and industrial applications.

The invention provides a system for measuring respiratory rate (RR) from a patient. The system includes an impedance pneumography (IP) sensor, connected to at least two electrodes, and a processing system that receives and processes signals from the electrodes to measure an IP signal. A motion sensor (e.g. an accelerometer) measures at least one motion signal (e.g. an ACC waveform) describing movement of a portion of the patient's body to which it is attached. The processing system receives the IP and motion signals, and processes them to determine, respectfully, frequency-domain IP and motion spectra. Both spectra are then collectively processed to remove motion components from the IP spectrum and determine RR. For example, during the processing, an algorithm determines motion frequency components from the frequency-domain motion spectrum, and then using a digital filter removes these, or parameters calculated therefrom, from the IP spectrum.

The invention provides a system for measuring respiratory rate (RR) from a patient. The system includes an impedance pneumography (IP) sensor, connected to at least two electrodes, and a processing system that receives and processes signals from the electrodes to measure an IP signal. A motion sensor (e.g. an accelerometer) measures at least one motion signal (e.g. an ACC waveform) describing movement of a portion of the patient's body to which it is attached. The processing system receives the IP and motion signals, and processes them to determine, respectfully, frequency-domain IP and motion spectra. Both spectra are then collectively processed to remove motion components from the IP spectrum and determine RR. For example, during the processing, an algorithm determines motion frequency components from the frequency-domain motion spectrum, and then using a digital filter removes these, or parameters calculated therefrom, from the IP spectrum.

The invention provides a system for measuring respiratory rate (RR) from a patient. The system includes an impedance pneumography (IP) sensor, connected to at least two electrodes, and a processing system that receives and processes signals from the electrodes to measure an IP signal. A motion sensor (e.g. an accelerometer) measures at least one motion signal (e.g. an ACC waveform) describing movement of a portion of the patient's body to which it is attached. The processing system receives the IP and motion signals, and processes them to determine, respectfully, frequency-domain IP and motion spectra. Both spectra are then collectively processed to remove motion components from the IP spectrum and determine RR. For example, during the processing, an algorithm determines motion frequency components from the frequency-domain motion spectrum, and then using a digital filter removes these, or parameters calculated therefrom, from the IP spectrum.

The present invention relates to a composition for expanding lymphocytes comprising at least two types of cytokines selected from interleukin 2 (IL-2), interleukin 15 (IL-15) and interleukin 21 (IL-21). It further relates to a Method of preparing a population of clinically relevant lymphocytes, comprising the steps of: obtaining a body sample from a mammal in particular a tissue sample or body liquid sample, comprising at least one lymphocyte and optionally separating the cells in the body sample, culturing the body sample in-vitro to expand and/or stimulate lymphocytes in the sample wherein the culturing comprises using IL-2, IL-15 and/or IL-21, and optionally determining the presence of clinically relevant lymphocyte in the cultured sample. The present invention also relates to an immunotherapy and the population of clinically relevant lymphocytes.

The invention provides a system for measuring respiratory rate (RR) from a patient. The system includes an impedance pneumography (IP) sensor, connected to at least two electrodes, and a processing system that receives and processes signals from the electrodes to measure an IP signal. A motion sensor (e.g. an accelerometer) measures at least one motion signal (e.g. an ACC waveform) describing movement of a portion of the patient's body to which it is attached. The processing system receives the IP and motion signals, and processes them to determine, respectfully, frequency-domain IP and motion spectra. Both spectra are then collectively processed to remove motion components from the IP spectrum and determine RR. For example, during the processing, an algorithm determines motion frequency components from the frequency-domain motion spectrum, and then using a digital filter removes these, or parameters calculated therefrom, from the IP spectrum.

MK (midkine) was found to rise in the blood or urine of patients with various types of cancers at early stage. Based on this finding, a method for detecting early cancer, comprising the step of measuring MK in blood or urine was completed.

The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

A fault inspection method and apparatus in which the scattergram is separated or objects of comparison are combined in such a manner as to reduce the difference between an inspection object image and a reference image. As a result, the difference between images caused by the thickness difference in the wafer can be tolerated and the false information generation prevented without adversely affecting the sensitivity.

The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

The present invention provides an optical device that is miniature, is highly sensitive and has a simplified package, and a manufacturing method thereof with high production efficiency and high reliability. The present invention is an optical device comprising: a photoelectric conversion element (50) having at least one photoelectric conversion portion (1) which is formed on a substrate (10); a sealing material (14); and a connection terminal (3). The optical device comprises an optical window which is an interface between the photoelectric conversion element (50) and an outside of the optical device; and an aperture (6) formed in the sealing material 14, and whose bottom face is the optical window. An entire face of the optical window is exposed to the outside. An optical adjustment element (13) may be formed on the interface. In this case, the interface between the optical adjustment element (13) and the outside is the optical window.

Exemplary embodiments include systems, methods, and compositions for the intra-operative detection of target tissue. At least one embodiment includes a fluorescence detection instrument that may be used for intra-operative detection of a fluorescent targeting agent, its binding site, and its interaction within cancer tissues. An exemplary embodiment is highly sensitive to the local deposition of fluorescence agents even at a low concentration. In at least one embodiment, the system includes a handheld navigation instrument that is usable to excite, detect, and report the fluorescent deposition of the targeting agent in real-time. In alternative embodiments, the system includes a wearable unit to excite, detect, and visually report the fluorescent deposition of the targeting agent to the user. The wearable unit includes eyewear that allow the user to perform image-guided surgery based on the near real-time fluorescence detection of the fluorescent targeting agent.

A broad spectrum neutron detector has a thermal neutron sensitive scintillator film interleaved with a hydrogenous thermalizing media. The neutron detector has negligible sensitivity to gamma rays and produces a strong and unambiguous signal for virtually all neutrons that interact with the hydrogenous volume. The interleaving of the layers of thermal neutron sensitive phosphors helps ensure that all parts of the thermalizing volume are highly sensitive.

The invention discloses a method for highly sensitive quantitative detection of quantum dot fluorescence immunochromatographic assay. The method includes: building a fluorescence immunochromatographic assay test strip on the basis of optimizing the structure of the test strip and components by the aid of excellent fluorescent characteristics of quantum dots and by means of combining quantum dot fluorescence labeling technology and immunochromatographic assay; detecting fluorescence signal strength of a quantitative belt and a quality control belt by the aid of a fluorescence quantometer and correcting the fluorescence strength of the quantitative belt by the aid of the quality control belt after immunochromatographic assay of the test strip; and further quantitatively detecting analyte according to a standard curve obtained by the fluorescence quantometer. The method is simple, rapid, accurate, low in cost and quite high in sensitivity. Compared with a conventional colloidal gold immunochromatographic assay method, the method has the advantages of fine labeling stability, low non-specificity, high sensitivity, wide linear range and accuracy in quantization. The method is applicable to samples such as blood samples, urine samples, spittle, excrement and the like, and can be applied to detection of critical illness, poison, food safety and the like.

A method for detecting one or more components of interest in a fluid-borne sample in a microchannel of a microfluidic device includes flowing the fluid-borne sample, in which the one or more components of interest are bound to a first labeled component binding moiety to form a first labeled complex, through a binding channel region of the microchannel. The binding channel region includes a second component-binding moiety reversibly bound to a wall surface of the binding channel region. At least a portion of the one or more components of interest is bound to the second component-binding moiety to form a second labeled complex. The second labeled complex is released from the binding channel region and flowed through a detection channel region of the microchannel, where the second labeled complex is detected.

Inventive methods and apparatus are useful for collecting magnetic materials in one or more magnetic fields and resuspending the particles into a dispersion medium, and optionally repeating collection/resuspension one or more times in the same or a different medium, by controlling the direction and rate of fluid flow through a fluid flow path. The methods provide for contacting derivatized particles with test samples and reagents, removal of excess reagent, washing of magnetic material, and resuspension for analysis, among other uses. The methods are applicable to a wide variety of chemical and biological materials that are susceptible to magnetic labeling, including, for example, cells, viruses, oligonucleotides, proteins, hormones, receptor-ligand complexes, environmental contaminants and the like.

Systems and methods are disclosed herein for verifying the quality of global navigation satellite system (GNSS) measurements. The system includes a GNSS receiver, a wireless communications device, and a fault detection processor. The GNSS receiver includes a GNSS antenna for receiving signals from a plurality of global navigation satellites and a processor for calculating a ranging measurement for each of the global navigation satellites from the GNSS receiver to the global navigation satellite. The wireless communications device receives ranging measurements from at least one other GNSS receiver. The fault detection processor performs a fault detection algorithm to determine if there is an anomaly affecting the ranging measurements of the GNSS receiver and the at least one other GNSS receiver.

The present invention provides methods and materials related to the detection of colorectal neoplasm-specific markers (e.g., markers associated with colorectal cancer, markers associated with adenoma) in or associated with a subject's stool sample. In particular, the present invention provides methods and materials for identifying mammals (e.g., humans) having a colorectal neoplasm by detecting the presence and level of indicators of colorectal neoplasia such as, for example, long DNA (e.g., quantified by Alu PCR) and the presence and level of tumor-associated gene alterations (e.g., mutations in KRAS, APC, melanoma antigen gene, p53, BRAF, BAT26, PIK3CA) or epigenetic alterations (e.g., DNA methylation) (e.g., CpG methylation) (e.g., CpG methylation in coding or regulatory regions of bmp-3, bmp-4, SFRP2, vimentin, septin9, ALX4, EYA4, TFPI2, NDRG4, FOXE1) in DNA from a stool sample obtained from the mammal.

Disclosed is a system for detecting a protease inside a cell. In one embodiment, the system includes a chimeric protein that comprises as covalently linked components: 1) at least one optionally masked signal protein; 2) at least one protease-specific cleavage site; and 3) at least one detectable amino acid sequence. The invention has a wide spectrum of applications including use in the detection of novel protease inhibitors inside cells and tissue.